Melior Announces Research Collaboration with Merck

EXTON, Pa., Nov. 7 /Xinhua-PRNewswire/ -- Melior Discovery, Inc.

announced today that it has signed a research collaboration with Merck & Co.,

Inc. to evaluate the activity of select Merck neuroscience compounds

utilizing elements of Melior’s in vivo Indication Discovery platform.

Under the terms of the agreement Merck will pay undisclosed fees for

priority access to aspects of Melior’s exclusively licensed platform.

“Our agreement represents a significant opportunity for both Merck and

Melior,” said Andrew Reaume, Ph.D., President and CEO of Melior. “Merck is

gaining access to a unique in vivo testing platform and this agreement

validates Melior’s Indication Discovery platform capabilities. We look

forward to a productive collaboration.”

Melior Discovery Overview

Melior Discovery is leading the transformation of pharmaceutical drug

repositioning with its unique Indication Discovery platform of multiplexed in

vivo models. It is using this capability to both build an internal pipeline

of development candidates as well as sharing this capability with pharma and

biotechnology company partners. In the former case, the Company is

identifying “privileged” compounds that have been discontinued by others

which it identifies through a close working relationship with Dr. Christopher

Lipinski. In its partnered arrangements, Melior offers pharmaceutical

partners an effective approach to expand their late-stage pipelines with

safe, high-quality drug candidates that originated from internal R&D efforts.

Melior Discovery is located in Exton, PA.